Related Experiment Video
Updated: May 17, 2026
12:38
Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells
Published on: November 6, 2021
A high-throughput screening assay using Krabbe disease patient cells.
Jameson Ribbens1, Grace Whiteley, Hirokazu Furuya
1McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Analytical Biochemistry
|November 10, 2012
Summary
Researchers developed a new high-throughput screening assay using patient cells to find drugs for Globoid Cell Leukodystrophy (Krabbe disease). This method identifies small molecules that boost the deficient GALC enzyme activity, offering new therapeutic potential for this neurodegenerative disorder.
Area of Science:
- Biochemistry
- Neuroscience
- Genetics
Background:
- Globoid cell leukodystrophy (GLD), or Krabbe disease, is a fatal lysosomal storage disorder caused by deficiency of the enzyme β-galactocerebrosidase (GALC).
- Current treatments like hematopoietic bone marrow transplantation can mitigate early symptoms but do not address progressive neurological decline.
- Small molecules offer therapeutic potential for GLD due to their ability to cross the blood-brain barrier and reach affected neural cells.
Purpose of the Study:
- To develop and validate a cellular high-throughput screening (HTS) assay for identifying small molecules that enhance residual β-galactocerebrosidase (GALC) activity in Globoid Cell Leukodystrophy (GLD) patient cells.
- To assess the feasibility of using transformed GLD patient fibroblasts for drug discovery targeting this neurodegenerative disease.
Main Methods:
- Primary skin fibroblasts from GLD patients were transformed with SV40 large T antigen to create a stable cell line maintaining GLD biochemical characteristics.
- A quantitative high-throughput screening (HTS) assay was established using a fluorescent substrate to measure residual GALC activity in high-density microplates.
- Pilot screening of a small compound library was performed, followed by validation of active compounds in primary GLD fibroblasts.
Main Results:
- The developed cellular HTS assay demonstrated robust statistical performance in pilot screening.
- Residual GALC activity was successfully measured in SV40-transformed GLD patient fibroblasts.
- The assay identified small molecules that exhibited concentration-response curves, indicating potential to enhance mutant GALC activity.
Conclusions:
- A feasible and robust cell-based HTS assay using live GLD patient cells has been developed.
- This assay can effectively screen for small molecules capable of enhancing residual GALC activity.
- The developed HTS assay holds promise for identifying novel therapeutic agents for Globoid Cell Leukodystrophy (Krabbe disease).
